Pertuzumab for metastatic HER2-positive gastric cancer – first line
NIHR HSRIC
Record ID 32016001030
English
Authors' recommendations:
Pertuzumab is a new drug to treat stomach cancer. It is delivered straight into the blood via a drip. Pertuzumab may help the body's immune system to fight the disease. Stomach cancer is an unusual type of cancer. Gastric and gastroesophageal junction adenocarcinoma are the most common types of stomach cancer. Pertuzumab may offer a new treatment option for people with stomach cancer that has one particular type of genetic mutation and whose disease has spread to other parts of the body.
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
http://www.hsric.nihr.ac.uk/topics/pertuzumab-for-metastatic-her2-positive-gastric-cancer-first-line/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Antibodies, Monoclonal, Humanized
- Receptor, ErbB-2
- Stomach Neoplasms
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.